Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlo Messina

Showing results (91-100 of 106) with videos related to

Pageof 11
Sort By:
Frontiers in Oncology|March 6, 2026
Impact of bone-targeting agents on the clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab: a sub-analysis of the Meet-URO 15 studyFrancesco Pantano, Andrea Malgeri, Ugo De Giorgi, et al.
Scientific Reports|June 17, 2026
Prognostic value of systemic inflammatory markers in avelumab maintenance for advanced urothelial carcinoma: the multicentric SAILOR analysisBrigida Anna Maiorano, Giandomenico Roviello, Alessandro Rizzo, et al.
Cancer Immunology, Immunotherapy : CII|February 3, 2026
Effectiveness of ICI-ICI versus ICI-TKI combinations in patients with IMDC intermediate- and poor-risk metastatic renal cell carcinoma: a sub-analysis of the MEET-URO 33 studyMichele Maffezzoli, Alessio Signori, Alessandro Acunzo, et al.
Nature Immunology|September 22, 2022
Cellular and transcriptional dynamics of human neutrophils at steady state and upon stressElisa Montaldo, Eleonora Lusito, Valentina Bianchessi, et al.
Therapeutic Advances in Medical Oncology|May 28, 2021
Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study)Sara Elena Rebuzzi, Alessio Signori, Giuseppe Luigi Banna, et al.
European Urology Oncology|November 29, 2024
Apalutamide in Metastatic Castration-sensitive Prostate Cancer: Results from the Multicenter Real-world ARON-3 StudyMatteo Santoni, Thomas Büttner, Pasquale Rescigno, et al.
Prostate Cancer and Prostatic Diseases|May 28, 2026
EMETPRO: a multicentric, international, retrospective analysis evaluating patients with metastatic hormone-sensitive prostate cancer with early progressionFabio Turco, Silke Gillessen, Giuseppe Salfi, et al.
Nature Medicine|March 2, 2023
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancerJoris van de Haar, Xuhui Ma, Salo N Ooft, et al.
Targeted Oncology|October 1, 2024
Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2<sup>EV</sup> StudyOndřej Fiala, Francesco Massari, Umberto Basso, et al.
Clinical Genitourinary Cancer|April 16, 2023
Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1)Matteo Santoni, Francesco Massari, Zin W Myint, et al.
Pageof 11

Showing results (91-100 of 106) with videos related to

Sort By:
Pageof 11
Frontiers in Oncology|March 6, 2026
Impact of bone-targeting agents on the clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab: a sub-analysis of the Meet-URO 15 studyFrancesco Pantano, Andrea Malgeri, Ugo De Giorgi, et al.
Scientific Reports|June 17, 2026
Prognostic value of systemic inflammatory markers in avelumab maintenance for advanced urothelial carcinoma: the multicentric SAILOR analysisBrigida Anna Maiorano, Giandomenico Roviello, Alessandro Rizzo, et al.
Cancer Immunology, Immunotherapy : CII|February 3, 2026
Effectiveness of ICI-ICI versus ICI-TKI combinations in patients with IMDC intermediate- and poor-risk metastatic renal cell carcinoma: a sub-analysis of the MEET-URO 33 studyMichele Maffezzoli, Alessio Signori, Alessandro Acunzo, et al.
Nature Immunology|September 22, 2022
Cellular and transcriptional dynamics of human neutrophils at steady state and upon stressElisa Montaldo, Eleonora Lusito, Valentina Bianchessi, et al.
Therapeutic Advances in Medical Oncology|May 28, 2021
Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study)Sara Elena Rebuzzi, Alessio Signori, Giuseppe Luigi Banna, et al.
European Urology Oncology|November 29, 2024
Apalutamide in Metastatic Castration-sensitive Prostate Cancer: Results from the Multicenter Real-world ARON-3 StudyMatteo Santoni, Thomas Büttner, Pasquale Rescigno, et al.
Prostate Cancer and Prostatic Diseases|May 28, 2026
EMETPRO: a multicentric, international, retrospective analysis evaluating patients with metastatic hormone-sensitive prostate cancer with early progressionFabio Turco, Silke Gillessen, Giuseppe Salfi, et al.
Nature Medicine|March 2, 2023
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancerJoris van de Haar, Xuhui Ma, Salo N Ooft, et al.
Targeted Oncology|October 1, 2024
Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2<sup>EV</sup> StudyOndřej Fiala, Francesco Massari, Umberto Basso, et al.
Clinical Genitourinary Cancer|April 16, 2023
Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1)Matteo Santoni, Francesco Massari, Zin W Myint, et al.
Pageof 11